Identification of polymorphisms in the 3′-untranslated region of the human pregnane X receptor (PXR) gene associated with variability in cytochrome P450 3A (CYP3A) metabolism

Xenobiotica

Volumn 40, Issue 2, 2010, Pages 146-162

  Oleson, L ^a   Von Moltke, L L ^b   Greenblatt, D J ^a   Court, M H ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

3 untranslated region (UTR); Cytochrome P450 (CYP) 3A (CYP3A); Haplotype; Pregnane X receptor (PXR); Single nucleotide polymorphism (SNP)

Indexed keywords

CYTOCHROME P450 3A; MIDAZOLAM; PREGNANE X RECEPTOR;

3' UNTRANSLATED REGION; ADULT; ARTICLE; CONTROLLED STUDY; DRUG HYDROXYLATION; FEMALE; GENE FREQUENCY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

3' UNTRANSLATED REGIONS; ADULT; AFRICAN AMERICANS; CELL LINE; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENE FREQUENCY; GENES, REPORTER; GENOTYPE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; LUCIFERASES; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN STRUCTURE, SECONDARY; RECEPTORS, STEROID; RNA, MESSENGER; YOUNG ADULT;

EID: 75649091527     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498250903420243     Document Type: Article

References (36)

1. Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, Sydow-Backman M, Ohlsson R, Postlind H, Blomquist P, Berkenstam A. (1998). Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci USA 95:12208-12213
2. Blumberg B, Sabbagh W, Jr, Juguilon H, Bolado J, Jr, van Meter CM, Ong ES, Evans RM. (1998). SXR, a novel steroid and xenobioticsensing nuclear receptor. Genes Dev 12:3195-3205
3. Bosch TM, Deenen M, Pruntel R, Smits PH, Schellens JH, Beijnen JH, Meijerman I. (2006). Screening for polymorphisms in the PXR gene in a Dutch population. Eur J Clin Pharmacol 62:395-399
4. Brodsky L, Ivanov, VV, Kalaidzidis YL, Leontovich, AM, Nikolaev, VK, Feranchuk, SI, Drachev, VA. (1995). GeneBee-NET:Internetbased server for analysing biopolymers structure. Biochemistry 60:923-928
5. Capasso M, Ayala F, Russo R, Avvisati RA, Asci R, Iolascon A. (2009). A predicted functional single-nucleotide polymorphism of bone morphogenetic protein-4 gene affects mRNA expression and shows a significant association with cutaneous melanoma in Southern Italian population. J Cancer Res Clin Oncol 135:1799-1807
6. Conne B, Stutz A, Vassalli JD. (2000). The 3″ untranslated region of messenger RNA: a molecular 'hotspot' for pathology? Nat Med 6:637-641
7. Fukuen S, Fukuda T, Matsuda H, Sumida A, Yamamoto I, Inaba T, Azuma J. (2002). Identification of the novel splicing variants for the hPXR in human livers. Biochem Biophys Res Commun 298:433-438
8. Greenblatt DJ, He P, von Moltke LL, Court MH. (2008). The CYP3 Family. In: Ioannides C, editor. Cytochrome P450: Role in the metabolism and toxicology of drugs and other xenobiotics. London: Royal Society of Chemistry. p. 354-383
9. Guengerich FP. (1999). Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1-17.
10. He P, Court MH, Greenblatt DJ, von Moltke LL. (2005). Genotype- phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Ther 77:373-387
11. He P, Court M, Greenblatt D, von Moltke L. (2006a). Human pregnane X receptor: genetic polymorphisms, alternative mRNA splice variants, and cytochrome P450 3A metabolic activity. J Clin Pharmacol 46:1356-1369
12. He P, Court MH, Greenblatt DJ, von Moltke LL. (2006b). Factors influencing midazolam hydroxylation activity in human liver microsomes. Drug Metab Dispos 34:1198-1207
13. Hesse LM, He P, Krishnaswamy S, Hao Q, Hogan K, von Moltke LL, Greenblatt DJ, Court MH. (2004). Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 14:225-238
14. Hill WG. (1974). Estimation of linkage disequilibrium in randomly mating populations. Heredity 33:229-239
15. Hughes TA. (2006). Regulation of gene expression by alternative untranslated regions. Trends Genet 22:119-122
16. Hustert E, Zibat A, Presecan-Siedel E, Eiselt R, Mueller R, Fuss C, Brehm I, Brinkmann U, Eichelbaum M, Wojnowski L, Burk O. (2001). Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos 29:1454-1459
17. King CR, Xiao M, Yu J, Minton MR, Addleman NJ, Van Booven DJ, Kwok PY, McLeod HL, Marsh S. (2007). Identification of NR1I2 genetic variation using resequencing. Eur J Clin Pharmacol 63:547-554
18. Koyano S, Kurose K, Ozawa S, Saeki M, Nakajima Y, Hasegawa R, Komamura K, Ueno K, Kamakura S, Nakajima T, Saito H, Kimura H, Goto Y, Saitoh O, Katoh M, Ohnuma T, Kawai M, Sugai K, Ohtsuki T, Suzuki C, Minami N, Saito Y, Sawada J (2002). Eleven novel single nucleotide polymorphisms in the NR1I2 (PXR) gene, four of which induce non-synonymous amino acid alterations. Drug Metab Pharmacokinet 17:561-565
19. Koyano S, Kurose K, Saito Y, Ozawa S, Hasegawa R, Komamura K, Ueno K, Kamakura S, Kitakaze M, Nakajima T, Matsumoto K, Akasawa A, Saito H, Sawada J (2004). Functional characterization of four naturally occurring variants of human pregnane X receptor (PXR): one variant causes dramatic loss of both DNA binding activity and the transactivation of the CYP3A4 promoter/ enhancer region. Drug Metab Dispos 32:149-154
20. Lamba J, Lamba V, Schuetz E. (2005). Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr Drug Metab 6:369-383
21. Lamba V, Yasuda K, Lamba JK, Assem M, Davila J, Strom S, Schuetz EG. (2004). PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators. Toxicol Appl Pharmacol 199:251-265
22. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. (1998). The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102:1016-1023
23. Meijerman I, Beijnen JH, Schellens JH. (2006). Herb-drug interactions in oncology: focus on mechanisms of induction. Oncologist 11:742-752
24. Olsen PH, Ambros V. (1999). The lin-4 regulatory RNA controls developmental timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the initiation of translation. Dev Biol 216:671-680
25. Özdemir V, Kalowa WA, Tang BK, Paterson AD, Walker SE, Endrenyi L, Kashuba AD. (2000). Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10:373-388
26. Spencer CC, Deloukas P, Hunt S, Mullikin J, Myers S, Silverman B, Donnelly P, Bentley D, McVean G. (2006). The influence of recombination on human genetic diversity. PLoS Genet 2:e148.
27. Stephens M, Smith NJ, Donnelly P. (2001). A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978-989
28. Takagi S, Nakajima, M, Mohri, T, Yokoi, T. (2008). Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J Biol Chem 283:9674-9680
29. Thummel KE, Wilkinson GR. (1998). In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389-430.
30. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W. (2005). Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435CT affects mRNA stability. Pharmacogenet Genomics 15:693-704.
31. Wang D, Sadee W. (2006). Searching for polymorphisms that affect gene expression and mRNA processing: example ABCB1 (MDR1). AAPS J 8:E515-20.
32. Westlind A, Löfberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M. (1999). Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5″-upstream regulatory region. Biochem Biophys Res Commun 259:201-205
33. Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR, Ingelman-Sundberg M. (2003). Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 31:755-761
34. Wilkinson GR. (1996). Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 24:475-490
35. Wrighton SA, VandenBranden M, Ring BJ. (1996). The human drug metabolizing cytochromes P450. J Pharmacokinet Biopharm 24:461-473
36. Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, Daly A, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Wrighton SA, Hancock M, Kim RB, Strom S, Thummel K, Russell CG, Hudson JR Jr, Schuetz EG, Boguski MS (2001). The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 11:555-572